$13.56
2.03% day before yesterday
Nasdaq, Jun 06, 10:00 pm CET
ISIN
US4579852082
Symbol
IART

Integra LifeSciences Holdings Corporation Stock price

$13.56
+0.81 6.35% 1M
-10.54 43.73% 6M
-9.12 40.21% YTD
-17.55 56.41% 1Y
-41.75 75.48% 5Y
-17.74 56.68% 10Y
-1.05 7.19% 20Y
Nasdaq, Closing price Fri, Jun 06 2025
+0.27 2.03%
ISIN
US4579852082
Symbol
IART
Sector

Key metrics

Market capitalization $1.05b
Enterprise Value $2.62b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.62
P/S ratio (TTM) P/S ratio 0.65
P/B ratio (TTM) P/B ratio 0.69
Revenue growth (TTM) Revenue growth 6.19%
Revenue (TTM) Revenue $1.62b
EBIT (operating result TTM) EBIT $167.97m
Free Cash Flow (TTM) Free Cash Flow $-25.46m
Cash position $273.30m
EPS (TTM) EPS $-0.38
P/E forward 32.81
P/S forward 0.63
EV/Sales forward 1.57
Short interest 10.12%
Show more

Is Integra LifeSciences Holdings Corporation a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,823 stocks worldwide.

Integra LifeSciences Holdings Corporation Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Integra LifeSciences Holdings Corporation forecast:

3x Buy
23%
6x Hold
46%
4x Sell
31%

Analyst Opinions

13 Analysts have issued a Integra LifeSciences Holdings Corporation forecast:

Buy
23%
Hold
46%
Sell
31%

Financial data from Integra LifeSciences Holdings Corporation

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
1,624 1,624
6% 6%
100%
- Direct Costs 675 675
17% 17%
42%
950 950
0% 0%
58%
- Selling and Administrative Expenses 673 673
11% 11%
41%
- Research and Development Expense 94 94
12% 12%
6%
183 183
31% 31%
11%
- Depreciation and Amortization 15 15
22% 22%
1%
EBIT (Operating Income) EBIT 168 168
33% 33%
10%
Net Profit -29 -29
172% 172%
-2%

In millions USD.

Don't miss a Thing! We will send you all news about Integra LifeSciences Holdings Corporation directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Integra LifeSciences Holdings Corporation Stock News

Neutral
Seeking Alpha
about one month ago
Integra LifeSciences Holdings Corporation (NASDAQ:IART ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants Chris Ward - Senior Director, Investor Relations Mojdeh Poul - President and Chief Executive Officer Lea Knight - Executive Vice President and Chief Financial Officer Conference Call Participants Young Li - Jefferies Iseult McMahon - BTIG Vik Chopra - Wells Fargo...
Neutral
GlobeNewsWire
about one month ago
PRINCETON, N.J., May 05, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the first quarter ending March 31, 2025.
Neutral
GlobeNewsWire
about 2 months ago
PRINCETON, N.J., April 18, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, will release first quarter 2025 financial results on Monday, May 5, 2025, prior to the market open. In conjunction with the earnings release, Integra's management team will host a conference call at 8:30 a.m. ET.
More Integra LifeSciences Holdings Corporation News

Company Profile

Integra LifeSciences Holdings Corp. engages in the manufacture and sale of medical instruments, devices, and equipment. It operates through the Codman Specialty Surgical, and Orthopedics and Tissue Technologies segments. The Codman Specialty Surgical segment refers to the company's neurosurgery business, which sells a full line of products for neurosurgery and neuro critical care such as tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment; and precision tools and instruments business, which sells instrument patterns and surgical and lighting products to hospitals, surgery centers, and dental, podiatry, and veterinary offices. The Orthopedics and Tissue Technologies segment includes offerings such as skin and wound repair, bone and joint fixation implants in the upper and lower extremities, bone grafts, and nerve and tendon repair. The company was founded by Richard E. Caruso in 1989 and is headquartered in Princeton, NJ.

Head office United States
CEO Mojdeh Poul
Employees 4,396
Founded 1989
Website www.integralife.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today